The pharmaceutical company—let us phone them Organization X, to the hell of it—will not be manufacturing MDMA tablets. This is different from a success of Molly you buy off a girl donning white fuzzy boots at an outside concert in the middle of summer. Business X will likely be creating the Lively pharmaceutical component, or API: the 99 p.c pu